

1 **Polygenic associations and causal inferences between serum**
2 **immunoglobulins and amyotrophic lateral sclerosis**

3 Xu Chen^{1,2*}, Xiaojun Shen², Xuzhuo Zhang¹, Yiqiang Zhan^{3,4} and Fang Fang⁴

4
5 ¹Department of Central Laboratory, Shenzhen Baoan Women's and Children's Hospital,
6 Jinan University, Shenzhen, China.

7 ²Institute of Maternal-Fetal Medicine, Shenzhen Baoan Women's and Children's Hospital,
8 Jinan University, Shenzhen, China.

9 ³German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.

10 ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

11

12

13 **Correspondence:**

14 Dr. Xu Chen. Department of Central Laboratory, Shenzhen Baoan Women's and Children's
15 Hospital, Jinan University, 56 YuLv Road, Shenzhen 518100, China. Phone: +86-
16 15989385199; Email: dr.xuchen@outlook.com

17 **Abstract**

18 Chronic inflammation might contribute to the development of amyotrophic lateral sclerosis (ALS),
19 the relationship between serum immunoglobulins and risk of ALS remains however unclear. In order
20 to overcome limitations like reverse causation and residual confounding commonly seen in the
21 observational studies, we applied molecular epidemiological analyses to examine the polygenic and
22 causal associations between serum immunoglobulins and ALS. Summary statistics from the large-
23 scale genome-wide association studies (GWAS) among European ancestry populations (~15000
24 individuals for serum immunoglobulins, and more than 36000 individuals for ALS) were accessed
25 from different consortia. The relationships between three types of serum immunoglobulins (IgA,
26 IgM, and IgG) and ALS were investigated in a discovery phase and then in a replication phase.
27 Polygenic risk score (PRS) analysis was performed with PRSice package to test the polygenic
28 association, and Mendelian randomization (MR) analysis was performed with TwoSampleMR
29 package to infer the causality. An inverse polygenic association was discovered between IgA and
30 ALS as well as between IgM and ALS. Such associations were however not replicated using a larger
31 GWAS of ALS, and no causal association was observed for either IgA-ALS or IgM-ALS. A positive
32 polygenic association was both discovered [odds ratio (OR) = 1.18, 95% confidence interval (CI):
33 1.12-1.25, $P=5.9\times 10^{-7}$] and replicated (OR=1.13, 95% CI: 1.06-1.20, $P=0.001$) between IgG and
34 ALS. A causal association between IgG and ALS was also suggested in both the discovery
35 (OR=1.06, 95%CI: 1.02-1.10, $P=0.009$) and replication (OR=1.07, 95%CI: 0.90-1.24, $P=0.420$)
36 analyses, although the latter was not statistically significant. This study suggests a shared polygenic
37 risk between serum IgG (as a biomarker for chronic inflammation) and ALS.

38

39

40 **Keywords**

41 Immunoglobulins, Amyotrophic lateral sclerosis, Polygenic risk score, Causal inference, Mendelian
42 randomization

43 **Introduction**

44 Amyotrophic lateral sclerosis (ALS) is a relatively rare but fatal neurodegenerative disease. Chronic
45 inflammation and altered immune responses have been suggested to contribute to the pathogenesis
46 of ALS [1]. The relationship between serum immunoglobulins, as known biomarkers for
47 inflammation and immune responses, and risk of ALS remains however unclear. In a previous study
48 [2], we did not find a statistically significant positive association between immunoglobulin G (IgG)
49 and risk of ALS [hazard ratio=1.04, 95% confidence interval (CI): 0.89-1.22; per 2.99 g/L increase
50 of IgG]. In the same study, we also found that during the 20 years before diagnosis, patients with
51 ALS had more rapidly declining levels of IgG compared to others. We speculate that the noted lack
52 of association between IgG and ALS might be attributable to both a real positive association
53 between IgG and ALS (i.e., higher levels of IgG lead to higher risk of ALS) and reverse causation
54 (i.e., ALS results in declined levels of IgG). In addition to reverse causation, observational studies
55 are also prone to other systemic errors, which collectively make it often difficult to infer causality
56 for associations noted in observational studies [3].

57
58 By using the summary statistics from large-scale genome-wide association studies (GWAS),
59 polygenic risk score (PRS) and Mendelian randomization (MR) analyses have added novel evidence
60 to support polygenic and causal relationships between several traits and ALS, corroborating
61 importantly findings from previous observational studies [4-6]. In this study, we used GWAS
62 summary statistics to assess the associations of genetically predicted levels of immunoglobulins with
63 the genetically predicted risk of ALS, and to test whether such associations are causal. Since IgG is a
64 biomarker for chronic inflammation, we hypothesized that there is a positive and causal relationship
65 between IgG and ALS. We additionally studied another two serum immunoglobulins (IgA and IgM,
66 two biomarkers that have rarely been studied in ALS) to assess the specificity of the IgG result.

67

68

69 **Methods**

70 **Summary statistics**

71 We used publicly available summary statistics of several GWAS within the European ancestry
72 population in this study. GWAS of serum immunoglobulins (IgA, IgM, and IgG) were conducted
73 among ~15000 individuals (from Iceland and Sweden), from which single nucleotide

74 polymorphisms (SNPs) with the association P-values $<1.0 \times 10^{-6}$ were available [7]. GWAS summary
75 statistics of ALS were obtained from two studies (available in the IEU GWAS database;
76 <https://gwas.mrcieu.ac.uk>, ID for ALS_2016: ieu-a-1085; ID for ALS_2018: ebi-a-GCST005647). In
77 the discovery analysis, summary statistics of ALS (ALS_2016) were obtained from a GWAS
78 performed among 36052 individuals (including 12577 patients with ALS and 23475 controls) by the
79 Project MinE group [8]. In the replication analysis, summary statistics of ALS (ALS_2018) were
80 obtained from a meta-analysis incorporating the results from ALS_2016 and another GWAS
81 including 40598 individuals (8229 patients with ALS and 32369 controls) [9]. Because we only used
82 GWAS summary statistics rather than individual-level data in this study, participant informed consent
83 and ethical review permit were waived according to the ethical review board of Shenzhen Baoan
84 Women's and Children's Hospital.

85
86 Using IgA, IgM, and IgG as the exposures (base traits) and ALS as the outcome (target trait), the
87 polygenic and causal associations of six exposure-outcome pairs (three in the discovery analysis and
88 three in the replication analysis) were investigated by PRS and MR analyses, respectively. Because
89 the values of immunoglobulins were standardized in the GWAS, we estimated accordingly odds
90 ratio (OR) per standard deviation of genetically predicted level for each type of immunoglobulin in
91 the present study.

92
93 **PRS analyses**
94 Polygenic associations were investigated by PRS analyses in Linux with PRSice package (version
95 1.25) [10]. For the summary statistics of each exposure, correlated SNPs were pruned by linkage
96 disequilibrium (LD) clumping with default parameter settings. Genotypes of the HapMap_ceu_all
97 (release 22, 60 individuals, 3.96 million SNPs) were used as the reference panel, clumping threshold
98 $p_1=p_2=0.5$, LD threshold $r^2=0.05$, and the distance threshold of 300Kb. Independent SNPs were then
99 extracted and included in 100000 quantiles with gradually increasing P-value thresholds (P_T , ranging
100 from 0 to 1.0×10^{-6} , in steps of 1.0×10^{-11} per quantile). The P_T of the quantile that explained the
101 largest variance of the target was defined as the best-fitted P_T .

102
103 **MR analyses**

104 Utilizing the instrumental variable (IV) methods (Fig. 1), MR analyses were performed in R (version
105 3.6.1) with TwoSampleMR package (version 0.5.2) [11]. Causal inference by MR analysis requires
106 three basic assumptions: 1) relevance, i.e., IVs have causal effects on the exposure (e.g., IgG); 2)
107 exclusion restriction, i.e., IVs affect the outcome (e.g., ALS), only through the exposure; and 3)
108 exchangeability or independence, i.e., no common causes exist between IVs and the outcome [12].
109 Lead SNPs from the genetic loci reported to be associated with each exposure were extracted from
110 the GWAS of immunoglobulins [7]. The associations of the SNPs with other traits (associations with
111 a P-value $<5 \times 10^{-8}$) were checked in GWAS Catalog (<https://www.ebi.ac.uk/gwas>) and excluded,
112 leaving independent lead SNPs after LD clumping as the IVs (Additional file: Table S1). The causal
113 relationship of each exposure-outcome pair was primarily examined by the inverse variance
114 weighted (IVW) method and complemented with another four methods (MR Egger regression,
115 weighted median, simple and weighted mode) as sensitivity analyses.

116

117

118 **Results and discussion**

119 Inverse polygenic associations were discovered for IgA-ALS and IgM-ALS, neither of the
120 associations was however replicated (Table 1, Additional file: Figs. 1-2). A positive polygenic
121 association between IgG and ALS was found both in the discovery and replication analyses (Table 1,
122 Additional file: Fig. 3). The OR was 1.18 (95% CI: 1.12-1.25, $P=5.9 \times 10^{-7}$) in the discovery analysis
123 and 1.13 (95%CI: 1.06-1.20, $P=0.001$) in the replication analysis.

124

125 In the MR analyses, causal association was not found for either IgA-ALS or IgM-ALS (Table 2),
126 regardless of the use of MR methods (Additional file: Figs. 4-5 and Table S2). For IgG-ALS (Table
127 2, Additional file: Fig. 6), a statistically significant causal association was found in the discovery
128 analysis (OR=1.06, 95% CI: 1.02-1.10, $P=0.009$). A causal positive association was also suggested
129 in the replication analysis, although not statistically significant (OR=1.07, 95%CI: 0.90-1.24,
130 $P=0.420$).

131

132 Utilizing PRS and MR analyses of large-scale GWAS of immunoglobulins and ALS, we provided
133 new evidence supporting a potentially causal positive association between IgG, but not IgA or IgM,
134 and risk of ALS.

135
136 Accumulating evidence supports that inflammation and altered immune responses are involved in
137 the different phases of ALS [13]. Physiological barriers (e.g., blood-brain barrier) and innate
138 immunity cells (e.g., macrophages) are fundamental in the maintenance and modulation of the
139 central nervous system, whereas chronic inflammation might lead to dysfunction of the neurons [14].
140 B cells play important roles in adaptive immunity, through producing immunoglobulins and
141 presenting antigens to T cells [15]. IgA constitutes 10-20% of serum immunoglobulins and is mainly
142 involved in the mucosal immune response. IgM constitutes 5-10% of serum immunoglobulins and is
143 the earliest released antibody during adaptive immune response. IgG constitutes ~75% of serum
144 immunoglobulins and can be transmitted through placental and blood-brain barriers [16].

145
146 Several studies have indicated a link between IgG and ALS. Deposit of IgG has been found in the
147 spinal cord and motor cortex of some ALS patients [17]. Prevalence of serum monoclonal
148 immunoglobulins (60%, including 44% IgG and 16% IgM) was found to be higher among ALS
149 patients than that of the control group (13%) [18]. High levels of 20 IgG antibodies were also found
150 to help diagnose ALS cases [19]. In our previous cohort study including more than half a million
151 participants with >20 years of follow-up, we found that per 2.99 g/L increase of IgG levels in blood,
152 there was a 4% increased risk of ALS, although the association was not statistically significant [2].
153 The lack of statistical significance might be multifactorial, including first a potentially real positive
154 association between IgG and ALS risk, a lack of statistical power due to the relatively small number
155 of ALS cases identified (N=152), and also reverse causation (i.e., patients with ALS had more
156 rapidly declining IgG levels, compared to individuals not developing ALS, during the 20 years
157 before ALS diagnosis). However, because genotypes are determined at birth and unchangeable
158 during the life course, our results about a potentially causal relationship between genetically
159 predicted IgG level and genetically predicted ALS risk are unlikely to be dependent on early or late
160 stage of ALS.

161
162 By using summary statistics from several large-scale GWAS, in the present study, we identified a
163 statistically significant positive polygenic association between IgG and ALS in both the discovery
164 and replication analyses. The association is further suggested to be causal in the MR analysis.
165 Although statistically significant result was only obtained in the discovery analysis, similar point

166 estimate was noted in the replication analysis. The differences between the discovery (ALS_2016)
167 and replication (ALS_2018) samples might have contributed to the lack of statistical significance in
168 the replication analysis. For instance, in the discovery GWAS (ALS_2016), patients with ALS and
169 controls were matched for age, sex, and geographic regions, whereas more than 50% of participants
170 in the replication GWAS (ALS_2018) were only matched for race/ethnicity.

171
172 In contrast to IgG, no clear polygenic association nor causal relationship was noted for IgA-ALS and
173 IgM-ALS. A recent observational study, including 489 patients with ALS and 17475 neurologically
174 healthy controls, also failed to detect an association between total serum IgA and ALS [20]. The
175 different result pattern between IgA, IgM and IgG might be partly explained by the fact that IgG is a
176 biomarker for chronic inflammation and bypasses the blood-brain-barrier, which might be more
177 relevant for neurodegenerative diseases including ALS, compared to the other immunoglobulins [21].

178
179 Even though we used the latest and largest GWAS of immunoglobulins, only two independent SNPs
180 could be selected as IVs for IgG. As a result, we could only use IVW methods in the MR analysis.
181 According to the current GWAS Catalog, no genome-wide significant association was identified
182 between the two IVs of IgG and other non-ALS traits. Interestingly, the two genes near these two
183 IVs are both biologically related to immune responses, neuroinflammation, and neurodegeneration.
184 Genetic variant rs7554873 is close to the *FCGR2B* (Fc fragment of IgG receptor IIb) gene on
185 chromosome 1. Protein FcγRIIB encoded by *FCGR2B* gene is a low-affinity receptor for the Fc
186 region of IgG. FcγRIIB involves in the regulation of antibodies produced by B-cells and in the
187 phagocytosis of immune complexes, it is also reported to mediate the inhibitory effect of aggregated
188 α-synuclein on microglial phagocytosis [22]. Genetic variant rs2133037 is close to the HLA-DQB1
189 (major histocompatibility complex, class II, DQ beta 1) gene on chromosome 6. Its encoded protein
190 HLA-DQB1 is also reported to be associated with immunity and neuronal survival [23].

191
192 In this study, we had only access to GWAS summary statistics data when testing the polygenic and
193 causal relationship between serum immunoglobulins (IgA, IgM, IgG) and ALS. Using a Mendelian
194 randomization analysis, our study is less prone to methodological limitations commonly seen in
195 observational studies such as confounding and reverse causation. Future studies with individual
196 genotype data are warranted in further understanding the roles of other factors (such as age, sex,

197 ethnicity, etc.) in the link between different immunoglobulins (especially IgG) and ALS. Further, to
198 test whether chronic inflammation is indeed a mechanism linking together IgG and ALS, the role of
199 IgG on other diseases (both diseases with a known link with chronic inflammation and diseases
200 without such a link) needs to be studied. Finally, as high levels of IgG antibodies were suggested to
201 improve the diagnosis of ALS [19], the potential use of IgG measurement in clinical diagnosis of
202 ALS needs to be further examined.

203

204

205 **Conclusions**

206 In conclusion, our study suggests a shared polygenic risk between serum IgG and ALS. The
207 causality between IgG and ALS needs to be further validated when more instrumental variables are
208 available and when different methods of causal inference are possible to use.

209

210

211 **Supplementary information**

212 **Additional file: Table S1.** Selection of instrumental variables for serum immunoglobulins in the
213 Mendelian randomization analyses. **Table S2.** Comparison of results from different methods in
214 Mendelian randomization analyses. **Figure S1.** Results from the polygenic risk score analyses
215 between serum IgA and ALS. **Figure S2.** Results from the polygenic risk score analyses between
216 serum IgM and ALS. **Figure S3.** Results from the polygenic risk score analyses between serum IgG
217 and ALS. **Figure S4.** Results from the Mendelian randomization analyses between serum IgA and
218 ALS. **Figure S5.** Results from the Mendelian randomization analyses between serum IgM and ALS.
219 **Figure S6.** Results from the Mendelian randomization analyses between serum IgG and ALS.

220

221

222 **List of abbreviations**

223 ALS: Amyotrophic lateral sclerosis; Ig: immunoglobulin; CI: confidence interval; GWAS: genome-
224 wide association study; PRS: polygenic risk score; MR: Mendelian randomization; SNP: single
225 nucleotide polymorphism; OR: odds ratio; LD: linkage disequilibrium; IVW: inverse variance
226 weighted; FCGR2B: Fc fragment of IgG receptor IIb; HLA-DQB1: Major histocompatibility
227 complex, class II, DQ beta 1.

228

229

230 **Declarations**

231 ***Acknowledgements:*** The authors would like to thank the Project MinE group and the ALS Variant
232 Server for sharing the summary statistics of GWAS on ALS.

233 ***Authors' contributions:*** X.C. and F.F. contributed to the conception and design of the study; X.C.,
234 X.S., X.Z., and Y.Z. contributed to acquisition and analyses of data; X.C., X.S., X.Z., Y.Z., and F.F.
235 contributed to drafting and revising the manuscript.

236 ***Funding:*** This project is supported by the Science, Technology and Innovation Bureau of Baoan
237 District (Grant No.: 2020JD445), the Swedish Research Council (Grant No.: 2019-01088) and
238 Karolinska Institutet (Senior Researcher Award and Strategic Research Area in Epidemiology).

239 ***Availability of data and materials:*** GWAS summary statistics of ALS were accessed from the
240 Project MinE group (<https://www.projectmine.com/research/download-data>) and the ALS Variant
241 Server (<http://als.umassmed.edu>).

242 ***Ethics approval and consent to participate:*** Because GWAS summary statistics rather than
243 individual-level data were used in this study, both informed consent and ethical approval were
244 waived according to the ethical review board in Shenzhen Baoan Women's and Children's Hospital.

245 ***Consent for publication:*** Not applicable.

246 ***Competing interests:*** The authors declare that they have no competing interests.

247

248

249 **References**

250 1. Beers DR, Appel SH: Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging
251 therapies. *Lancet Neurol* 2019, 18:211-220.


252 2. Yazdani S, Mariosa D, Hammar N, Andersson J, Ingre C, Walldius G, Fang F: Peripheral immune
253 biomarkers and neurodegenerative diseases: A prospective cohort study with 20 years of follow-up.
254 *Ann Neurol* 2019, 86:913-926.

- 255 3. Vandenberg JP, Broadbent A, Pearce N: Causality and causal inference in epidemiology: the need for
256 a pluralistic approach. *Int J Epidemiol* 2016, 45:1776-1786.
- 257 4. Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F: Polygenic link between blood lipids and amyotrophic
258 lateral sclerosis. *Neurobiol Aging* 2018, 67: e201-e206.
- 259 5. Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, Consortium I, International ALSGC,
260 Tienari PJ, Stone DJ, et al: Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis.
261 *Ann Neurol* 2019, 85:470-481.
- 262 6. Zhan Y, Fang F: Smoking and amyotrophic lateral sclerosis: A mendelian randomization study. *Ann*
263 *Neurol* 2019, 85:482-484.
- 264 7. Jonsson S, Sveinbjornsson G, de Lapuente Portilla AL, Swaminathan B, Plomp R, Dekkers G, Ajore R, Ali
265 M, Bentlage AEH, Elmer E, et al: Identification of sequence variants influencing immunoglobulin levels.
266 *Nat Genet* 2017, 49:1182-1191.
- 267 8. van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, van der Spek RA, Vosa U,
268 de Jong S, Robinson MR, et al: Genome-wide association analyses identify new risk variants and the
269 genetic architecture of amyotrophic lateral sclerosis. *Nat Genet* 2016, 48:1043-1048.
- 270 9. Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, et
271 al: Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. *Neuron* 2018, 97:1268-1283.
- 272 10. Euesden J, Lewis CM, O'Reilly PF: PRSice: Polygenic Risk Score software. *Bioinformatics* 2015, 31:1466-
273 1468.
- 274 11. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon
275 R, et al: The MR-Base platform supports systematic causal inference across the human phenome. *Elife*
276 2018, 7:e34408.
- 277 12. Armon C: Smoking is a cause of amyotrophic lateral sclerosis. High low-density lipoprotein cholesterol
278 levels? *Unsure. Ann Neurol* 2019, 85:465-469.
- 279 13. Molteni M, Rossetti C: Neurodegenerative diseases: The immunological perspective. *J Neuroimmunol*
280 2017, 313:109-115.
- 281 14. Novellino F, Sacca V, Donato A, Zaffino P, Spadea MF, Vismara M, Arcidiacono B, Malara N, Presta I,
282 Donato G: Innate Immunity: A Common Denominator between Neurodegenerative and
283 Neuropsychiatric Diseases. *Int J Mol Sci* 2020, 21(3):1115.
- 284 15. Sabatino JJ, Jr., Probstel AK, Zamvil SS: B cells in autoimmune and neurodegenerative central nervous
285 system diseases. *Nat Rev Neurosci* 2019, 20:728-745.
- 286 16. Chen K, Magri G, Grasset EK, Cerutti A: Rethinking mucosal antibody responses: IgM, IgG and IgD join
287 IgA. *Nat Rev Immunol* 2020, 20(7):427-441.
- 288 17. Donnenfeld H, Kascsak RJ, Bartfeld H: Deposits of IgG and C3 in the spinal cord and motor cortex of ALS
289 patients. *J Neuroimmunol* 1984, 6(1):51-57.

- 290 18. Duarte F, Binet S, Lacomblez L, Bouche P, Preud'homme JL, Meininger V: Quantitative analysis of
291 monoclonal immunoglobulins in serum of patients with amyotrophic lateral sclerosis. *J Neurol Sci* 1991,
292 104(1):88-91.
- 293 19. May C, Nordhoff E, Casjens S, Turewicz M, Eisenacher M, Gold R, Brüning T, Pesch B, Stephan C,
294 Voitalla D, et al: Highly immunoreactive IgG antibodies directed against a set of twenty human proteins
295 in the sera of patients with amyotrophic lateral sclerosis identified by protein array. *PLoS One* 2014,
296 9(2):e89596.
- 297 20. Crayle J, Elmallah M, Sleasman J, Bedlack R: Total serum immunoglobulin A in ALS. *Amyotroph Lateral*
298 *Scler Frontotemporal Degener* 2020, 1-5.
- 299 21. Watson N, Ding B, Zhu X, Frisina RD: Chronic inflammation - inflammaging - in the ageing cochlea: A
300 novel target for future presbycusis therapy. *Ageing Res Rev* 2017, 40:142-148.
- 301 22. Choi YR, Kang SJ, Kim JM, Lee SJ, Jou I, Joe EH, Park SM: FcγRIIB mediates the inhibitory effect of
302 aggregated alpha-synuclein on microglial phagocytosis. *Neurobiol Dis* 2015, 83:90-99.
- 303 23. Hallberg P, Smedje H, Eriksson N, Kohnke H, Daniilidou M, Ohman I, Yue QY, Cavalli M, Wadelius C,
304 Magnusson PKE, et al: Pandemrix-induced narcolepsy is associated with genes related to immunity and
305 neuronal survival. *EBioMedicine* 2019, 40:595-604.
- 306

307 **Figure 1. Illustration of the Mendelian randomization analysis**

308 Mendelian randomization analysis utilizes the instrumental variable (IV) methods to infer the
309 causality between exposure and outcome. Because alleles are randomly assigned during mitosis,
310 restricted single nucleotide polymorphisms (SNPs) could be used as instrumental variables to test the
311 causal effect of exposure on the outcome. ALS: amyotrophic lateral sclerosis.



312

313

314 **Table 1. Polygenic associations between serum immunoglobulins and ALS in PRS analyses**

Base	Target	Best-fitted P_T	n_{SNP}	OR	SE	r^2 (%)	P-value
IgA	ALS_2016	8.6000×10^{-10}	54	0.861	0.032	0.059	4.2×10^{-6}
	ALS_2018	7.0001×10^{-7}	43	0.948	0.031	0.004	0.085
IgM	ALS_2016	4.8000×10^{-10}	47	0.905	0.032	0.028	0.002
	ALS_2018	3.5010×10^{-8}	42	1.051	0.028	0.004	0.074
IgG	ALS_2016	5.1001×10^{-7}	49	1.181	0.033	0.069	5.9×10^{-7}
	ALS_2018	5.7001×10^{-7}	22	1.130	0.036	0.014	0.001

315 PRS=polygenic risk score; ALS=amyotrophic lateral sclerosis; Best-fitted P_T =association P-value
316 threshold of the quantile that explained the largest variance of the target; n_{SNP} =numbers of
317 independent single nucleotide polymorphisms (SNPs) included in the best-fitted quantile; OR: odds
318 ratio per standard deviation of genetically determined level for each type of immunoglobulin;
319 SE=standard error; r^2 = the proportion of the target variation explained by SNPs in the best-fitted
320 quantile.

321

322 **Table 2. Causal inferences between serum immunoglobulins and ALS in the MR analyses**

Base	Target	n _{SNP}	OR _{IVW}	SE _{IVW}	P _{IVW}	Het_P _{IVW}
IgA	ALS_2016	6	0.968	0.022	0.148	0.206
	ALS_2018	6	0.880	0.100	0.201	0.125
IgM	ALS_2016	5	0.996	0.015	0.787	0.574
	ALS_2018	5	1.021	0.054	0.706	0.874
IgG	ALS_2016	2	1.056	0.021	0.009	0.617
	ALS_2018	2	1.073	0.087	0.420	0.407

323 MR=mendelian randomization; ALS=amyotrophic lateral sclerosis; n_{SNP}= numbers of independent
324 single nucleotide polymorphisms (SNPs) uses as instrumental variables; OR: odds ratio per standard
325 deviation of genetically determined level for each type of immunoglobulin; SE=standard error;
326 IVW= inverse variance weighted method; Het_P=P-value of heterogeneity.

327